Pylarify Truvu is a drug owned by Aphelion Llc. It is protected by 6 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 09, 2037. Details of Pylarify Truvu's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11851407 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL |
Jun, 2037
(11 years from now) | Active |
| US10947197 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
Jun, 2037
(11 years from now) | Active |
| US8778305 | PSMA-binding agents and uses thereof |
Sep, 2030
(4 years from now) | Active |
| US12070513 | PSMA-binding agents and uses thereof |
Jul, 2029
(3 years from now) | Active |
| US9861713 | PSMA-binding agents and uses thereof |
Jul, 2029
(3 years from now) | Active |
| US8487129 | Heterodimers of glutamic acid |
Nov, 2027
(1 year, 6 months from now) | Active |
Several oppositions have been filed on Pylarify Truvu's European patents.
EP oppositions
can significantly impact the timeline for the generic launch of drugs. If an opposition results in the
revocation or
amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an
earlier entry
of generic versions into the market. To help you estimate the potential early arrival of Pylarify Truvu's generic, the next section provides detailed information on
ongoing and past
EP oppositions related to Pylarify Truvu patents.
Pylarify Truvu's Oppositions Filed in EPO
Pylarify Truvu has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 23, 2021, by Lewis Silkin Llp. This opposition was filed on patent number EP18150494A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP19214298A | Jan, 2023 | Telix Innovations S.A. | Granted and Under Opposition |
| EP18150494A | Sep, 2021 | Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg | Revoked |
| EP18150494A | Sep, 2021 | POLSERVICE KANCELARIA RZECZNIKOW PATENTOWYCH SP. Z O.O. | Revoked |
| EP18150494A | Sep, 2021 | Lewis Silkin LLP | Revoked |
US patents provide insights into the exclusivity only within the United States, but
Pylarify Truvu is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Pylarify Truvu's family patents as well as insights into
ongoing legal events
on those patents.
Pylarify Truvu's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Pylarify Truvu's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 09, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Pylarify Truvu Generics:
There are no approved generic versions for Pylarify Truvu as of now.
Alternative Brands for Pylarify Truvu
There are several other brand drugs in the same treatment category and using the same active ingredient (Piflufolastat F-18) as Pylarify Truvu. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Telix |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Piflufolastat F-18. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Progenics Pharms Inc |
|
About Pylarify Truvu
Pylarify Truvu is a drug owned by Aphelion Llc. Pylarify Truvu uses Piflufolastat F-18 as an active ingredient. Pylarify Truvu was launched by Aphelion in 2026.
Can you believe Pylarify Truvu received compensation for the extended wait time during the regulatory approval process?
A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent. The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.
Approval Date:
Pylarify Truvu was approved by FDA for market use on 06 March, 2026.
Active Ingredient:
Pylarify Truvu uses Piflufolastat F-18 as the active ingredient. Check out other Drugs and Companies using Piflufolastat F-18 ingredient
Dosage:
Pylarify Truvu is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1mCi/mL-120mCi/mL | SOLUTION | Prescription | INTRAVENOUS |